<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="614">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00895882</url>
  </required_header>
  <id_info>
    <org_study_id>7009-019</org_study_id>
    <secondary_id>2009_586</secondary_id>
    <nct_id>NCT00895882</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)</brief_title>
  <official_title>A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Treatment-Naive Patients With Chronic Genotype 1 Hepatitis C Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and efficacy of vaniprevir when
      administered concomitantly with pegylated interferon (peg-IFN) and ribavirin (RBV) to treat
      treatment-naive genotype 1 hepatitis C virus (HCV)-infected patients.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of patients achieving SVR24 in Treatment Regimens 1 to 4</measure>
    <time_frame>24 weeks after end of study therapy</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the safety and tolerability of the MK7009 treatment regiments as assessed by review of the accumulated safety data</measure>
    <time_frame>72 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>1) Proportion of patients achieving SVR24 in Treatment Regimen 5</measure>
    <time_frame>1) 24 weeks after end of study therapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Genotype 1 Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaniprevir 300 mg b.i.d. + peg-IFN + RBV for 12 weeks, followed by placebo to vaniprevir + peg-IFN + RBV for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaniprevir 300 mg b.i.d. + peg-IFN + RBV for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaniprevir 600 mg b.i.d. + peg-IFN + RBV for 12 weeks, followed by placebo to vaniprevir + peg-IFN + RBV for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaniprevir 600 mg b.i.d. + peg-IFN + RBV for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaniprevir 600 mg q.d. + peg-IFN + RBV for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to vaniprevir + peg-IFN + RBV for 24 weeks, followed by peg-IFN + RBV for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vaniprevir (MK7009)</intervention_name>
    <description>vaniprevir 300 mg soft gel capsules twice daily.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: vaniprevir (MK7009)</intervention_name>
    <description>vaniprevir 600 mg soft gel capsules twice daily.</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Pegylated Interferon (peg-IFN) alfa-2a</intervention_name>
    <description>Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Ribavirin</intervention_name>
    <description>Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo to vaniprevir</intervention_name>
    <description>Placebo to vaniprevir soft gel capsules twice daily.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has chronic genotype 1 HCV infection

          -  Patient has had a liver biopsy without evidence of cirrhosis

          -  Patient has had an eye exam prior to the start of study

          -  Female patients capable of having children and male patients with female partners
             capable of having children agree to use two forms of birth control throughout the
             study

        Exclusion Criteria:

          -  Patient has had previous treatment with: 3 or more doses IFN, peg-IFN, and/or RBV;
             and stopped treatment due to intolerance of one of the drugs; other antiviral or
             investigational therapies or vaccines for HCV

          -  Female patient is pregnant or breastfeeding

          -  Patient has chronic hepatitis not caused by HCV

          -  Patient has evidence of cirrhosis of the liver

          -  Patient has HIV

          -  Patient has active hepatitis B infection

          -  Patient has non-genotype 1 HCV infection

          -  Patient consumes excessive amounts of alcohol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 21, 2015</lastchanged_date>
  <firstreceived_date>May 6, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
